Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;7(6):1713-1717.
doi: 10.3892/etm.2014.1646. Epub 2014 Mar 28.

Clinical analysis of pulmonary infection in hemodialysis patients

Wei Ren  1 , Huixuan Pan  1 , Peng Wang  1 , Lei Lan  1 , Wei Chen  1 , Yan Wang  1 , Lijun Ni  1 , Li Peng  1
Affiliations

Clinical analysis of pulmonary infection in hemodialysis patients

Wei Ren et al. Exp Ther Med. 2014 Jun.

Abstract

The present study aimed to investigate the pathogen distribution and drug resistance of lung infections in hemodialysis to guide clinical empirical pharmacy. The clinical data of 116 hemodialysis patients with pulmonary infection were analyzed. The majority of the 82 pathogens isolated from the sputa of patients were Gram-negative bacteria (accounting for 71.95%). The results of the drug sensitivity test suggested that Gram-negative bacilli had low resistance rates to piperacillin and tazobactam, imipenem and amikacin, while Gram-positive cocci had a low resistance rate to vancomycin. All resistance rates of the pathogens to other common antimicrobials were >50%. The pathogens resulting in lung infections in hemodialysis patients were mainly Gram-negative bacteria and were significantly resistant to various antibacterials. Results of the this study demonstrate that pathological examination should be performed as early as possible and effective antimicrobial agents should be chosen according to drug sensitivity test results.

Keywords: drug sensitivity test; hemodialysis; pulmonary infection; sputum culture.

PubMed Disclaimer

References

    1. Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662–668. - PubMed
    1. O’Seaghdha CM, Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int. 2005;25:534–540. - PubMed
    1. Hakim RM, Himmerlfarb J. Hemodialysis access failure: a call to action. Kidney Int. 1998;54:1029–1040. - PubMed
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266. - PubMed
    1. Soni R, Horowitz B, Unruh M. Immunization in end-stage renal disease: opportunity to improve outcomes. Semin Dial. 2013;26:416–426. - PubMed

LinkOut - more resources